Literature DB >> 28833722

Killing two birds with one stone: response to pembrolizumab in a patient with metastatic melanoma and B-cell chronic lymphocytic leukaemia.

M Arenbergerova1, A Fialova1, P Arenberger1, S Gkalpakiotis1, T Jirasek2,3, A Srp4, A Novotna5, H Frankova6.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28833722     DOI： 10.1111/jdv.14537

Source DB:  PubMed          Journal:  J Eur Acad Dermatol Venereol        ISSN： 0926-9959            Impact factor:   6.166


× No keyword cloud information.
  2 in total

Review 1.  Tackling Cancer Resistance by Immunotherapy: Updated Clinical Impact and Safety of PD-1/PD-L1 Inhibitors.

Authors:  Shifaa M Abdin; Dana M Zaher; El-Shaimaa A Arafa; Hany A Omar
Journal:  Cancers (Basel)       Date:  2018-01-25       Impact factor: 6.639

2.  The impact of immune checkpoint inhibitors in patients with chronic lymphocytic leukemia (CLL): A protocol for a systematic review and meta-analysis of randomized controlled trials.

Authors:  Aviwe Ntsethe; Phiwayinkosi Vusi Dludla; Tawanda Maurice Nyambuya; Siphamandla Raphael Ngcobo; Bongani Brian Nkambule
Journal:  Medicine (Baltimore)       Date:  2020-07-10       Impact factor: 1.817
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.